

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
23 September 2021 (23.09.2021)



(10) International Publication Number  
**WO 2021/188770 A1**

(51) International Patent Classification:  
*A61K 39/395* (2006.01) *C07K 16/18* (2006.01)

(21) International Application Number:  
PCT/US2021/022914

(22) International Filing Date:  
18 March 2021 (18.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
62/991,232 18 March 2020 (18.03.2020) US

(71) Applicants: **MEMORIAL SLOAN KETTERING CANCER CENTER** [US/US]; 1275 York Avenue, New York, New York 10065 (US). **CERAMEDIX HOLDING, LLC** [US/US]; 555 Madison Avenue, Suite 1201, New York, New York 10022 (US).

(72) Inventor; and

(71) Applicant: **KOLESNICK, Richard** [US/US]; c/o Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065 (US).

(72) Inventors: **TINKELENBERG, Arthur**; c/o Ceramedix Holding, LLC, 555 Madison Avenue, Suite 1201, New York, New York 10022 (US). **WANG, Jordon Kuo-Ming**; c/o LakePharma, Inc., 520 Harbor Boulevard, Belmont, California 94002 (US). **WU, Yinan**; c/o LakePharma, Inc., 520 Harbor Boulevard, Belmont, California 94002 (US). **WANG, Yong**; c/o LakePharma, Inc., 520 Harbor Boulevard, Belmont, California 94002 (US). **LEVY, Raphael**; c/o LakePharma, Inc., 520 Harbor Boulevard, Belmont, California 94002 (US).

(74) Agent: **EWING, James F.** et al.; FOLEY & LARDNER LLP, 3000 K Street NW, Suite 600, Washington, District of Columbia 20007 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: ANTI-CERAMIDE ANTIBODIES




FIG. 1

(57) Abstract: The present disclosure provides compositions of anti-ceramide antibodies and antigen-binding fragments thereof. The disclosure further provides methods of preventing or inhibiting cell death in a subject in need thereof comprising administering the anti-ceramide antibodies or antigen-binding fragments to a subject. The subject in need thereof may suffer from an autoimmune disease, GI syndrome, or GvHD.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*